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Expanded safety experience with lenalidomide plus
dexamethasone in relapsed or refractory multiple myeloma
The outcomes for many patients with multiple myeloma
(MM) have been improved in the past few years with the
introduction of the immunomodulatory drugs thalidomide
and lenalidomide, and the proteasome inhibitor bortezomib,
though the disease is usually still incurable (Kyle & Rajkumar,
2004; Anderson et al, 2007). Lenalidomide (Revlimid
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Summary
Lenalidomide gained Food and Drug Administration (FDA) approval for
treatment of patients with relapsed or refractory multiple myeloma (MM) in
combination with dexamethasone in June 2006. In April 2005, the FDA and
patient advocacy groups requested an expanded access programme to both
provide lenalidomide to patients likely to beneﬁt and obtain additional safety
information. Relapsed/refractory MM patients received lenalidomide 25
mg/d (days 1–21) and dexamethasone 40 mg/d (days 1–4, 9–12, and 17–20 of
cycles 1–4; days 1–4 only from cycle 5 onwards), in 4-week cycles until
disease progression, study drug discontinuation, or lenalidomide approval.
Of the 1438 patients enrolled, 60% were male, median age was 64 years,
and 61Æ7% had Durie-Salmon stage III disease. Median time on study was
15Æ4 weeks (range: 0Æ1–49Æ1) and median dose was 25 mg. The most common
adverse events (AEs) were haematological (49%), gastrointestinal (59%), and
fatigue (55%). The most common grade ‡3 AEs were haematological (45%),
fatigue (10%), and pneumonia (7%). The most common serious AEs were
pneumonia (8%), pyrexia (4%), and deep-vein thrombosis (3%). Primary
cause of death was disease progression (10%). Safety data conﬁrmed known
AEs of lenalidomide plus dexamethasone therapy in patients with relapsed/
refractory MM.
Keywords: multiple myeloma, relapsed/refractory, lenalidomide plus dexa-
methasone, combination therapy.
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analogue of thalidomide that is effective (with a good safety
proﬁle) in the treatment of patients with relapsed or
refractory MM (Corral et al, 1999; Hideshima et al, 2000;
Richardson et al, 2002, 2006; Dimopoulos et al, 2007; Weber
et al, 2007), and transfusion-dependent International Prog-
nostic Scoring System (IPSS)-deﬁned Low- and Int-1-risk
myelodysplastic syndromes (MDS) associated with a deletion
5q [del(5q)] chromosomal abnormality (List et al, 2006). On
29 June 2006, the US Food and Drug Administration (FDA)
approved lenalidomide given in combination with dexameth-
asone for the treatment of patients with MM who had
received prior therapy, based on the results from two parallel,
randomized, double-blind, placebo-controlled phase III trials
(Dimopoulos et al, 2007; Weber et al, 2007). In June 2007,
the European Medicines Agency approved lenalidomide for
the same indication. In pre-planned interim analyses of these
two trials, patients treated with the lenalidomide and
dexamethasone combination had a signiﬁcantly longer time
to disease progression compared with patients treated with
dexamethasone alone. Based on these results, an Independent
Data Safety Monitoring Board recommended unblinding of
the studies so that all enrolled patients could have access to
lenalidomide.
In April 2005, over a year before FDA approval and while
lenalidomide therapy for relapsed or refractory MM was
under review, the Oncology Division of the FDA, along with
myeloma patient advocacy groups, requested that the manu-
facturer of lenalidomide, Celgene Corporation, establish an
‘expanded access programme’. This would make lenalidomide,
in combination with dexamethasone, available to patients with
relapsed or refractory MM with a high likelihood of beneﬁt.
On this basis, the safety study protocol MM-016 was initiated.
Here we provide the safety analysis of patients with relapsed
or refractory MM who participated in this expanded access
trial.
Patients and methods
Patient eligibility and enrolment
The institutional review boards or ethics committees at each
participating centre approved the study protocol and all
patients provided written informed consent. The inclusion and
exclusion criteria for the study were the same as for the pivotal
phase III studies (MM-009 and MM-010) (Dimopoulos et al,
2007; Weber et al, 2007). Patients were eligible if they were
aged ‡18 years, and had MM that had progressed after ‡2
cycles of anti-myeloma treatment or relapsed with progressive
disease after treatment. Patients were required to have
measurable levels of myeloma paraprotein in the serum
(‡5Æ0 g/l) or urine (‡0Æ2 g secreted in a 24-h collection
sample), and an Eastern Cooperative Oncology Group
(ECOG) performance status score of £2. Prior thalidomide
or radiation therapy was allowed. Radiation therapy initiated
prior to or at baseline was permitted concurrent to study
treatment, but all other anti-myeloma medication or other
therapy had to be discontinued prior to the ﬁrst study dose.
Women of childbearing potential had to have two negative
pregnancy tests before starting the study treatment, and had
to agree to use two reliable methods of contraception
simultaneously or to practise complete abstinence from
heterosexual intercourse from 28 d before the start of
lenalidomide treatment until 28 d after treatment discontin-
uation. While participating in the study, and for at least 28 d
after treatment discontinuation, men (including those who
had undergone a successful vasectomy) had to agree to use a
latex condom during sexual contact with women of child-
bearing potential. Participating men and women had to agree
not to donate blood (and men also not to donate semen or
sperm) during the study, and for at least 28 d after treatment
discontinuation.
Patients were excluded from the study if they had: a prior
history of malignancy other than MM, except for basal cell or
squamous cell skin carcinoma or carcinoma in situ of the
cervix or breast (unless the patient had been free of disease for
at least 1 year); known hypersensitivity to thalidomide or
dexamethasone; prior history of uncontrollable side-effects to
dexamethasone treatment; development of desquamating rash
while taking thalidomide; or neuropathy grade ‡2. Patients
with any of the following laboratory abnormalities were also
excluded from the study: those with an absolute neutrophil
count of <1Æ0 · 10
9/l; those with a platelet count of <75 · 10
9/
l (for patients in whom <50% of bone marrow nucleated cells
were plasma cells), or a platelet count of <30 · 10
9/l (for
patients in whom ‡50% of bone marrow nucleated cells were
plasma cells); serum creatinine >221 lmol/l; serum aspartate
aminotransferase (AST) or alanine aminotransferase (ALT)
levels >3· upper limit of normal; and serum total bilirubin
>34Æ2 lmol/l.
Patients were enrolled in the study starting September 2005.
Accrual in the USA was terminated following FDA approval of
the MM indication in June 2006. Enrolment is continuing in
Canada and is planned to continue until the drug is approved
by the Canadian regulatory authorities. This report is a
summary of the trial results from initiation on 6 September
2005 to termination of the US involvement on 21 September
2006.
Treatment schedule and assessments
Patients were instructed to self-administer oral lenalidomide at
a starting dose of 25 mg/d for 21 d, and dexamethasone
40 mg/d on days 1–4, 9–12, and 17–20. Each cycle was
repeated every 28 d. Beginning with cycle 5, the dexametha-
sone schedule was reduced to 40 mg/d for days 1–4, every
28 d. Treatment was continued as tolerated, until disease
progression or unacceptable adverse events as per the dose
modiﬁcation guidelines. After baseline evaluation at study
entry, patients were seen at study visits every 2 weeks for the
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documentation of disease progression or if treatment was
discontinued for any reason.
Although the investigators assessed the patients for disease
progression, there was no formal efﬁcacy evaluation performed
in this study. Safety evaluations included: vital signs; haema-
tology; serum chemistries; serum thyroid-stimulating hor-
mone; thyroid function (T3,T 4); electrocardiogram; serum and
urine beta-human chorionic gonadotrophin (for female
patients of childbearing potential only); and adverse events.
The severity of adverse events was graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (National Cancer Institute, 2006). An internal
data monitoring committee reviewed ongoing safety data
throughout the study. The members of the committee included
representatives from regulatory affairs and drug safety, a lead
product safety physician, a biostatistician, and three medical
ofﬁcers (one an oncologist).
Lenalidomide was supplied by the manufacturer in bottles
containing 21 (25-mg or 5-mg) capsules. Commercial supplies
of dexamethasone were used. Antithrombotic therapy, such as
daily aspirin, was recommended as prophylaxis for deep-vein
thrombosis (DVT); daily prophylaxis with antibiotics was
recommended for all patients; and erythropoietin was recom-
mended for chronic transfusion-dependent anaemia, but none
of these was mandated. Other therapies considered necessary
for the well-being of the patient (e.g. analgesics, antihista-
mines, growth factors, and transfusions of red blood cells,
platelets, or fresh-frozen plasma) were allowed at the discretion
of the investigator.
Dose modiﬁcations
Lenalidomide doses were interrupted for: grade 3 or 4
neutropenia; thrombocytopenia with a platelet count of
<30 · 10
9/l; grade 2 allergic reaction or hypersensitivity;
hyperthyroidism or hypothyroidism of grade ‡2; grade 2
neuropathy; and other lenalidomide-related grade 3 or 4
adverse events. Treatment was resumed at a lower dose level
after the adverse event improved to grade 2 or better.
Lenalidomide treatment was discontinued for grade ‡3 rash/
desquamation, grade 3 or 4 allergic reaction or hypersensitiv-
ity, and grade 3 or 4 neuropathy. For patients with grade ‡3
venous thrombosis or embolism, the dose was interrupted and
anticoagulation therapy was started. Lenalidomide treatment
was to be restarted at the same dose level at the physician’s
discretion.
The protocol included four lenalidomide dose reduction
levels. Level )1 included maintenance of the 25-mg starting
dose, supplemented by granulocyte colony-stimulating factor
according to the American Society of Clinical Oncology
(ASCO) guidelines (Ozer et al, 2000). This level was recom-
mended for patients with grade 3 or 4 neutropenia only. For all
other adverse events requiring lenalidomide dose reduction,
the dose reductions were Level )2 (15 mg), Level )3 (10 mg),
and Level )4 (5 mg). Lenalidomide treatment was discontin-
ued for patients who could not tolerate dose Level )4.
Dexamethasone doses were interrupted or reduced in
response to dyspepsia, gastric or duodenal ulcers, gastritis,
oedema, confusion or mood alterations, muscle weakness,
hyperglycaemia, and acute pancreatitis. There were three
dexamethasone dose reduction levels: 40 mg/d for 4 d every
2 weeks; 40 mg/d for 4 d every 4 weeks; and 20 mg/d for 4 d
every 4 weeks.
For both lenalidomide and dexamethasone, dose escalation
was not permitted after dose reduction.
Statistical design and analysis
The primary objective of this trial was to provide lenalidomide
to patients with a high likelihood of beneﬁt. The secondary
objective was to obtain additional safety data. The study end-
point was safety, including assessment of type, frequency,
severity, and relationship of side-effects to study treatment.
Data from all patients who received at least one dose of
lenalidomide were included in the safety analyses. Continuous
demographic and baseline variables were summarized using
descriptive statistics, whereas categorical variables were sum-
marized in frequency tabulations. The median exposure to
lenalidomide was calculated as the average dose over all the days
between the ﬁrst and last dose date, including the 7 d off-drug
in each 28-d cycle and any interruption periods. Thus a dose
exposure of 18Æ75 mg/d was 100% of the scheduled daily dose
of 25 mg for 21 d of every 28-d cycle with no interruption.
Results
Between 6 September 2005 and 21 September 2006, a total of
1438 patients from 69 centres in the USA and Canada were
enrolled. Patient characteristics are summarized in Table I. The
median age was 64 years (range: 29–91 years). Prior treatments
included thalidomide, alkylators, bortezomib, high-dose che-
motherapy/stem cell transplantation, and anthracycline. The
median time on study was 15Æ4 weeks (range: 0Æ1–49Æ1 weeks).
The median exposure to lenalidomide was 18Æ8 mg/d (range:
1Æ7–28Æ6 mg), over a median of 15Æ1 weeks (range: 0Æ1–
49Æ1 weeks). This was 100% of the scheduled daily dose of
lenalidomide 25 mg for 21 d. A total of 424 (29Æ5%) patients
had at least onedose reduction (dose level )2through )4), with
306 patients requiring one dose reduction, 89 patients requiring
two dose reductions, 28 patients requiring three dose reduc-
tions, and one patient requiring four dose reductions (the ﬁrst
dose reduction level for this patient was 20 mg). The adverse
events most commonly causing dose reduction were thrombo-
cytopenia (1Æ6%), neutropenia (1Æ5%), and pneumonia (1Æ3%).
Adverse events
The most common adverse events (all grades) were haemato-
logical, gastrointestinal, fatigue, and muscle cramps (Table II).
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copenia, and anaemia) were manageable with dose reductions
and resulted in only 3Æ75% of patients discontinuing lenalido-
mide treatment. Hypokalaemia, hyperglycaemia not otherwise
speciﬁed (NOS), and blurred vision were noted in less than
10% of patients. The most common grade ‡3 adverse events
were haematological, fatigue, and pneumonia (Table III). The
most common grade 4 adverse events were thrombocytopenia
(7Æ1%), neutropenia (5Æ2%), anaemia (1Æ2%), and pneumonia
(1Æ0%). At least one grade 3 or 4 adverse event was reported in
69Æ7% of patients. The most common serious adverse events
were pneumonia, pyrexia, DVT, and thrombocytopenia
(Table IV).
Neuropathic symptoms (neuropathy NOS, peripheral neu-
ropathy NOS, peripheral sensory neuropathy, peripheral
motor neuropathy, and polyneuropathy NOS) were reported
by 18Æ2% of patients on the study at some point during their
treatment. The majority (224 of 263 [85Æ2%] patients) had
grade 1 or 2 events. Of the 18Æ2% patients who experienced
neuropathic symptoms, 73Æ9% had a prior history. Two thirds
(67%) of all patients on study had a prior history of
neuropathy.
Venous thromboembolic events (VTEs) of all grades
occurred in 8Æ3% of patients with a median duration of 12 d
(range: 1–113 d). VTEs included DVT (6Æ1%), pulmonary
embolism (1Æ5%), thrombosis (0Æ8%), jugular vein thrombosis
(0Æ1%); thrombosis (0Æ9%; thrombosis, phlebothrombosis),
unspeciﬁed phlebitis (0Æ3%), and unspeciﬁed embolism
(0Æ2%). Grades 3/4/5 VTEs occurred in 5Æ8% of patients.
Arterial thromboembolic events (ATEs) occurred in 2Æ9% of
patients. ATEs included myocardial infarction (0Æ5%), tran-
sient ischaemic attack (0Æ4%), cerebrovascular accident (0Æ4%),
and thrombotic stroke (0Æ1%). Only 1Æ8% of these patients had
Table I. Patient demographics and disease characteristics (N = 1438).
Characteristic
Patients
n %
Age, years
Median 64
Range 29–91
Sex
Male 863 60
Female 575 40
Race*
White 1191 82Æ8
Black 154 10Æ7
Hispanic 47 3Æ3
Asian/Paciﬁc Islander 26 1Æ8
American Indian/Alaska native 2 0Æ1
Other 18 1Æ3
Stage of disease (Durie-Salmon)
I 176 12Æ2
II 358 24Æ9
III 887 61Æ7
Missing 17 1Æ2
Prior multiple myeloma therapy 
Alkylators 846 58Æ8
Anthracycline 566 39Æ4
High-dose chemotherapy/
stem cell transplantation
758 52Æ7
Bortezomib 824 57Æ3
Vinca alkaloid 548 38Æ1
Thalidomide 1094 76Æ1
Other 865 60Æ2
Medical history 
Neuropathy 958 66Æ6
Venous thromboembolism 227 15Æ8
*Percentages may add up to more than 100% as patients were allowed
to select more than one race.
 Percentages may add up to more than 100% as more than one
response was allowed.
Table II. Most common grade 1–4 adverse events due to any cause
reported in ‡10Æ0% of patients (N = 1438).
Adverse event
Patients
n %
Patients with ‡1 adverse event 1404 97Æ6
General
Fatigue 796 55Æ4
Asthenia 220 15Æ3
Pyrexia 215 15Æ0
Peripheral oedema 202 14Æ0
Gastrointestinal
Constipation 341 23Æ7
Diarrhoea NOS 297 20Æ7
Nausea 272 18Æ9
Musculoskeletal
Muscle cramp 338 23Æ5
Back pain 190 13Æ2
Arthralgia 145 10Æ1
Nervous system
Dizziness 170 11Æ8
Neuropathy NOS 145 10Æ1
Haematological
Neutropenia 425 29Æ6
Anaemia NOS 340 23Æ6
Thrombocytopenia 306 21Æ3
Respiratory
Dyspnoea NOS 235 16Æ3
Cough 223 15Æ5
Infections
Pneumonia NOS 155 10Æ8
Upper respiratory tract infection NOS 144 10Æ0
Psychiatric
Insomnia 286 19Æ9
Skin
Rash NOS 186 12Æ9
Metabolic
Anorexia 147 10Æ2
NOS, not otherwise speciﬁed.
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ATEs.
Incidence of dose reductions and discontinuations due to
adverse events
Overall, 18Æ5% of patients enrolled in the trial discontinued
treatment with lenalidomide due to adverse events. The most
common causes of lenalidomide discontinuation due to adverse
events were thrombocytopenia, neutropenia, pneumonia, and
sepsis (Table V). Other reasons for treatment discontinuation
included commercial availability of the drug in the USA
(46Æ7%), disease progression (18Æ5%), death (5Æ1%), and
withdrawal of consent (4Æ4%). Neutropenia (17Æ8%), throm-
bocytopenia (9Æ2%), fatigue (8Æ3%), pneumonia (3Æ5%),
pyrexia (3Æ5%), and anaemia (3Æ3%) were the most common
adverse events that led to dose reductions, interruptions, or
discontinuation. The median time to the ﬁrst dose reduction,
interruption, or discontinuation was 36 d (range: 1–282 d).
Deaths
Overall, 216 deaths (15%) were reported in the trial, with 125
deaths (8Æ7%) occurring within 30 d from the last dose. The
most frequent causes of death were disease progression
(10Æ2%) and adverse events (4Æ3%); 1% of deaths were due
to adverse events related to the study drug.
Discussion
Thalidomide emerged as an anticancer agent after investigators
demonstrated its antineoplastic activity in haematological
malignancies and, in particular, for the treatment of patients
with MM (Singhal et al, 1999; Rajkumar et al, 2000, 2002,
2006; Barlogie et al, 2001; Weber et al, 2003). Lenalidomide
was developed to further enhance efﬁcacy while avoiding the
teratogenicity, sedation, peripheral neuropathy, and severe
constipation associated with thalidomide therapy (Richardson
et al, 2002, 2006; Rajkumar et al, 2005; Dimopoulos et al,
2007; Weber et al, 2007).
The expanded access trial permitted lenalidomide plus
dexamethasone to be available to patients in the USA and
Canada while the drugawaited FDA approval for use in patients
with MM. During the course of this trial, the FDA approved the
Table III. Most common grade 3 or 4 adverse events due to any cause
reported in >2Æ0% of patients (N = 1438).
Adverse event
Patients
n %
Patients with ‡1 grade 3 or 4 adverse event 1002 69Æ7
Haematological
Neutropenia 315 21Æ9
Thrombocytopenia 195 13Æ6
Anaemia NOS 111 7Æ7
Febrile neutropenia 35 2Æ4
General
Fatigue 149 10Æ4
Asthenia 53 3Æ7
Infections
Pneumonia NOS 102 7Æ1
Metabolic
Hyperglycaemia NOS 61 4Æ2
Dehydration 38 2Æ6
Musculoskeletal
Back pain 39 2Æ7
Muscle weakness NOS 37 2Æ6
Investigations
Neutrophil count decreased 31 2Æ2
Respiratory
Dyspnoea NOS 57 4Æ0
Venous thromboembolism
Deep-vein thrombosis 65 4Æ5
NOS, not otherwise speciﬁed.
Table IV. Most common serious adverse events (N = 1438).
Serious adverse event
Patients
n %
Pneumonia 117 8Æ1
Pyrexia 54 3Æ8
Deep-vein thrombosis 43 3Æ0
Thrombocytopenia 42 2Æ9
Dehydration 36 2Æ5
Febrile neutropenia 36 2Æ5
Anaemia 35 2Æ4
Dyspnoea 29 2Æ0
Table V. Most common adverse events leading to treatment discon-
tinuation due to any cause reported in >0Æ5% of patients (N = 1438).
Adverse event
Patients
n %
Patients with ‡1 adverse event
leading to discontinuation of study drug
266 18Æ5
Thrombocytopenia 23 1Æ6
Neutropenia 21 1Æ5
Pneumonia NOS 19 1Æ3
Sepsis NOS 14 1Æ0
Fatigue 11 0Æ8
Pancytopenia 11 0Æ8
Anaemia NOS 10 0Æ7
Asthenia 10 0Æ7
Multiple myeloma 9 0Æ6
Rash NOS 9 0Æ6
Acute renal failure 9 0Æ6
Dyspnoea NOS 8 0Æ6
Pyrexia 8 0Æ6
NOS, not otherwise speciﬁed.
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risk MDS associated with a del(5q) chromosomal abnormality.
This trial was continued as the daily dose of lenalidomide used
for the treatment of MDS was 10 mg, and that for MM is
25 mg. This trial provides a model of how regulatory agencies,
advocacy groups, healthcare providers, and industry can work
together to quickly provide an effective treatment to a large
number of patients in need, while a regimen with clearly
demonstrated safety and activity awaits approval.
The type and frequency of adverse events from over 1400
patients with MM enrolled in this trial are consistent with
results from the phase III studies used to register the drug in the
USA and Europe. Compared with the MM-009 study, a similar
number of patients discontinued treatment due to adverse
events (19Æ8% vs. 18Æ5%, respectively) (Weber et al, 2007).
The most commonly observed grade 3 or 4 adverse events in
this study occurred at a similar frequency as those reported for
the pivotal MM-009 and MM-010 studies (Dimopoulos et al,
2007; Weber et al, 2007). Among the MM-009 and MM-010
patients who were treated with lenalidomide and dexameth-
asone, thrombosis occurred in 23% of patients who received
concomitant erythropoietic therapy, such as epoetin alfa or
darbepoetin, compared to 5% who did not (Knight et al,
2006). The lower frequency of thromboembolic events that
occurred in this trial may be attributed to the strong
recommendation that daily aspirin or other thromboprophy-
lactic therapy continued to be used, which has been shown to
decrease the incidence of VTE without bleeding complications
(Baz et al, 2005; Rajkumar et al, 2005, 2006; Zonder et al,
2006).
The majority of patients (67%) on this trial had a prior
history of neuropathy. Most neuropathy observed in this trial
was grade 1 or 2. Although 18Æ2% of patients reported the
occurrence of neuropathy, it is unclear if this represented
residual neurological damage from prior therapies associated
with neurological damage, such as thalidomide, vincristine,
and bortezomib (Richardson et al, 2003, 2005; Glasmacher
et al, 2006).
As with other studies of lenalidomide, most adverse events
that occurred were well managed by lenalidomide dose
reductions or interruptions, and symptom-control medica-
tions (according to study protocol).
In conclusion, the safety proﬁle of lenalidomide therapy in
conjunction with dexamethasone for relapsed or refractory
MM in an expanded access programme is consistent with the
two randomized, placebo-controlled trials that were the basis
for US and European approval.
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